NCT02582879

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,504 (actual)
• Sponsor: Pharmacyclics LLC. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is designed as a multicenter, prospective, observational registry of CLL/SLL patients who are initiating approved oral kinase inhibitors, BCL-2 inhibitors or other approved anti-CLL therapies/regimens. The study will characterize treatment patterns and their association with patient characteristics, healthcare resource utilization, and clinical outcomes, as well as patient-reported outcome (PRO) measures.

Detailed description

This multicenter, prospective, observational registry of CLL patients is designed to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors and other approved anti-CLL therapies/ regimens. The registry will provide information on regimens used to treat first-line and later lines of CLL as well as the sequencing of treatment regimens. The registry will also evaluate the association of these treatment patterns with patient characteristics, healthcare resource utilization, and functional outcomes including patient-reported HRQoL. These data will provide information to physicians that may help guide clinical practice and appropriate use of therapies, and will also provide information on HRQoL and healthcare resource utilization that will be of interest to healthcare decision makers.

Conditions

• Chronic Lymphocytic Leukemia (CLL)

Timeline

• Start date: 2015-09-01
• Primary completion: 2021-07-21
• Completion: 2021-07-21
• First posted: 2015-10-21
• Last updated: 2022-07-22

Locations

192 sites across 1 country: United States